Navigation Links
Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
Date:3/19/2013

dustries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, our ability to co-promote Kineret and continue our commercialization of KRYSTEXXA; our ability to retain the personnel; competition from existing therapies and therapies that are currently under development; whether we are able to obtain financing, if needed; economic, political and other risks associated with foreign operations; risks of maintaining protection for our intellectual property; risks of an adverse determination in intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical industry and other important factors set forth more fully in our reports filed with the Securities and Exchange Commission, to which investors are referred for further information. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements, which speak only as of the date of publication of this press release. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not have a policy of updating or revising forward-looking statements and, except as required by law, assume no obligation to update any forward-looking statements.

SVNT-I

(Tables to Follow)SAVIENT PHARMACEUTICALS, INC. 

CONSOLIDATED BALANCE SHEETS(In thousands, except share data) December 31,
2012December 31,
2011ASSETSCurrent Assets:Cash and cash equivalents$

50,332$

114,094Short-term investments45,94955,694Accounts receivable, net4,3414,737Invento
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Savient Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
3. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
4. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
5. Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies
6. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz
7. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
8. AVANIR Pharmaceuticals To participate in two conferences in March
9. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
10. Serialization in Pharmaceuticals, a Webinar Presented by Xtalks
11. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Today the Academy of Model Aeronautics (AMA) ... of Appeals for the D.C. Circuit challenging the FAA’s Interpretation ... Federal Register on June 25, 2014. , The AMA ... text and intent of the FAA Modernization and Reform Act ... on any new rules or regulations regarding model aircraft that ...
(Date:8/22/2014)... direct observations of how facets form and develop ... sophisticated and effective nanocrystal design and reveal that ... growth breaks down at the nanoscale. , Researchers ... Berkeley National Laboratory (Berkeley Lab) used highly sophisticated ... camera to capture the physical mechanisms that ...
(Date:8/22/2014)... 2014 Research and Markets has ... Gel Permeation Chromatography (GPC) Industry Report 2014" report ... China Gel Permeation Chromatography (GPC) Industry Report is a ... the global gel permeation chromatography industry with a focus ... basic overview of the industry including definitions, classifications, applications ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 The ... model organisms can be accelerated by exome sequencing. ... manufacturing technologies, the custom SeqCap EZ Developer system ... , Mr. Watson will additionally present how he ... commercially available human and mouse exome kits. With ...
Breaking Biology Technology:AMA Files Petition for Review of FAA’s Interpretive Rule 2Shaping the future of nanocrystals 2Shaping the future of nanocrystals 3Shaping the future of nanocrystals 4Global and China Gel Permeation Chromatography (GPC) Industry Report 2014 2Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2
... Cedara Software said it has acquired through ... medical software company in Paris. Cedara is he Toronto-based ... information technology company headquartered in Milwaukee. , ,It will ... managment, which has been installed in 25 French facilities. ...
... revenues for the quarter ended December 31 were up 18 ... quarter, compared to $1.6 million a year ago. , ,A ... this year and projected cashflow break-even sometime in the next ... net loss was $1.6 million for the quarter, compared to ...
... Fifty-two University of Wisconsin undergrads are going to ... Thursday and Friday for creative inventions that could turn ... for Creativity and Tong Prototype Prize reward students for ... At this year's Innovation Days, undergrads will show off ...
Cached Biology Technology:
(Date:8/21/2014)... international standards process, will be available soon and will ... published in the OnlineFirst version of Nutrition in ... of the American Society for Parenteral and Enteral Nutrition ... of misconnection that can be harmful and even fatal ... join medical devices, components, and accessories to deliver fluids ...
(Date:8/21/2014)... have developed a novel and versatile modeling strategy to ... new materials as well as for studying polyelectrolytes, including ... to model much larger and more complex polyelectrolyte systems, ... Li, lead author of a paper on the work ... Materials Science and Engineering. "This is a big step ...
(Date:8/20/2014)... a study of 158 pregnant teenagers in Rochester, NY, ... intentional consumption of ice, cornstarch, vacuum dust, baby powder ... Cornell study. , Moreover, such teens had significantly lower ... eat nonfood substances. , Pregnant teens, regardless of pica, ... lead to iron deficiency and anemia. Low iron in ...
Breaking Biology News(10 mins):New feeding tube connectors will improve patient safety 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2Pica in pregnant teens linked to low iron 2
... High-intensity focused ultrasound emitted in short pulses is ... to cancerous cells without destroying healthy tissue, according ... the journal Radiology. , High-intensity focused ultrasound (HIFU) ... destroy tumors through long and continuous exposures that ...
... grow these cells are costly and don't produce cells ... embryonic stem cells, said Shang-Tian Yang, a professor of ... Federal rules forbid the federal funding of research on ... the National Institutes of Health's Human Embryonic Stem Cell ...
... of the NIH public access policy announced earlier this ... , BioMed Central welcomes the announcement of the ... The NIH calls on all of its grantees to deposit ... of Medicine's PubMed Central and make them freely available within ...
Cached Biology News:Pulsating ultrasound enhances gene therapy for tumors 2Researchers devise way to mass-produce embryonic stem cells 2Researchers devise way to mass-produce embryonic stem cells 3BioMed Central welcomes the new National Institutes of Health public access policy 2
Rabbit polyclonal to TRPM8 (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 79054 SwissProtID: Q3YFM7...
Phospho- (Ser/Thr) PDK1 Docking Motif (18A2) Mouse mAb...
Component in MasterPure™ Purification Kits...
Chlamydia pneumoniae (TWAR)...
Biology Products: